AIM
AGIO icon

ARK Investment Management’s Agios Pharmaceuticals AGIO Stock Holding History

ARK Investment Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,399
Closed -$894K – 201
2017
Q3 		$894K Buy
13,399
+2,686
+25% +$161K 0.11% 93
2017
Q2 		$551K Buy
10,713
+4,267
+66% +$218K 0.11% 80
2017
Q1 		$376K Buy
6,446
+1,891
+42% +$90.6K 0.11% 64
2016
Q4 		$190K Buy
+4,555
New +$239K 0.07% 79

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

ARK Investment Management's AGIO Position: Q4 2017 in Review

ARK Investment Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2017, closing a stake of 13,399 shares — an estimated $894K sold.

ARK Investment Management first reported a position in AGIO in Q4 2016 and held it in 4 quarters. The position peaked at $894K in Q3 2017. 178 funds tracked by Wall St. Rank hold AGIO as of Q4 2017.

  • ARK Investment Management reported no remaining Agios Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • ARK Investment Management sold 13,399 Agios Pharmaceuticals shares in Q4 2017, an estimated $894K.
  • ARK Investment Management first reported a position in Agios Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • ARK Investment Management's Agios Pharmaceuticals position peaked at $894K in Q3 2017.
  • 178 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2017.

Based on ARK Investment Management's 13F filing for Q4 2017, filed 12 Feb 2018.